Firefighters accept extraordinary risk in the line of duty. But for Brian Ryll, president of the Professional Fire Fighters of New Hampshire, the most insidious threat is the one that often goes unseen: cancer.
Gilead HIV Policy Directors Dan Murphy and Pema McGuinness recently developed a series of policy papers that warn of the consequences if governments fail to take steps to prioritize and invest in HIV.
At CooperCompanies, our mission of improving lives one person at a time is grounded in enhancing health and wellness worldwide. For us, it’s not just business. It’s deeply personal.
Abbott was recently recognized as an industry leader on The Global Child Forum’s State of Children's Rights and Business Global Benchmark 2021 for implementing policies and practices that address and protect the rights of children.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced the signing of a long-term supply agreement with the United Nations Children’s Fund (UNICEF) to facilitate broad global access for molnupiravir, an investigational
In 1999, with the country ravaged by HIV and its future existence literally in doubt, Botswana embarked on an aggressive plan to curtail the transmission of the virus from mother to child.
The Dr. Martin Luther King, Jr. holiday marks a National Day of Service and an important time of reflection. In 1966 Rev. Dr. Martin Luther King, Jr. spoke at the National Convention of the Medical Committee for Human Rights
Northern Trust is helping to fund a $4.75 million comprehensive home-based asthma program, known as the New York Healthy Homes Collaborative, to improve quality of life for 850 New York City children and adults on Medicaid.
As a middle school math teacher in Woodbridge, Virginia, Dr. Arik King saw firsthand how boys of color trailed their peers in test scores, attendance, and graduation rates—part of an alarming and persistent national trend.
Illumina Inc. (NASDAQ: ILMN) today announced a partnership with Boehringer Ingelheim to develop companion diagnostics (CDx) for several programs in Boehringer Ingelheim's oncology pipeline. The partnership aims to accelerate the development of therapy selection and precision medicines for patients with advanced cancer.
Illumina, Inc. (NASDAQ: ILMN) today announced a multi-year partnership with Agendia N.V., a world leader in precision oncology for breast cancer, to co-develop in vitro diagnostic (IVD) tests for oncology testing. The partnership is intended to advance the use of next-generation sequencing (NGS) for decentralized oncology testing and aligns with Illumina's approach to IVD partnerships in oncology. Agendia joins Illumina's growing portfolio of more than 30 IVD partners developing over 40 sequencing-based solutions for cancer prognosis, therapy selection and other applications.
Cascale organizes and participates in a series of events, leveraging its position as a global convener of close to half the sector to bring together...
FedEx Cares is our global community engagement program and one way that we live out our purpose of connecting people and possibilities. Our goal is to...
Antea Group's health and safety consultants understand what it takes to help make a positive impact on safety culture. Read blogs, insights, and more...
The SCS Kingfisher certification mark is showing up on an increasing number of products around the world. It differentiates companies that are making...
